A detailed history of Federated Hermes, Inc. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 598 shares of TRVI stock, worth $2,529. This represents 0.0% of its overall portfolio holdings.

Number of Shares
598
Previous 773 22.64%
Holding current value
$2,529
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.58 - $3.51 $451 - $614
-175 Reduced 22.64%
598 $1,000
Q1 2024

May 14, 2024

SELL
$1.3 - $3.7 $230 - $654
-177 Reduced 18.63%
773 $2,000
Q4 2023

Jan 31, 2024

BUY
$1.06 - $2.05 $1,007 - $1,947
950 New
950 $1,000
Q3 2022

Nov 14, 2022

BUY
$1.54 - $4.28 $1,342 - $3,732
872 New
872 $1,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.